Seeking Alpha

Repros Therapeutics reports six month Androxal data

  • Repros Therapeutics (RPRX) reports six-month interim results from a study of "Androxal treatment of secondary hypogonadal men and its effect on bone mineral density."
  • No bone loss was observed compared to placebo.
  • Some improvement in bone mineral density was observed in the Androxal group.
  • Topline, 12-month results are due in Q2 2014. (PR)
  • Shares +0.9% AH.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio: